ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB at the Karolinska Institute of Stockholm. We are focused on addressing antimicrobial resistance (AMR), severe blood stream infections, and metastatic circulating tumor cell removal from the blood in high-risk patient populations with field-deployable versions for biodefense and military.
ExThera Medical Corporation is a privately held Delaware C corporation with a focus in the development and commercialization of innovative device-based clinical treatments for both drug-resistant and drug-susceptible bloodstream infections.
ExThera Medical is currently in a capital growth phase: SERIES C ROUND IS LIVE. Please contact us to learn more:
Erin Borger | Director
ExThera Medical Corporation